generic drugs

Summary

Summary: Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies.

Top Publications

  1. ncbi Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
    Nicole Gebran
    Pharmacy Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    Ann Saudi Med 26:192-9. 2006
  2. ncbi Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes
    Frederick Andermann
    Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
    Epilepsia 48:464-9. 2007
  3. ncbi A comparative analysis of generics markets in five European countries
    L Garattini
    Center for Health Economics CESAV, Mario Negri Institute for Pharmacolological Research, Ranica, Bergamo, Italy
    Health Policy 51:149-62. 2000
  4. ncbi Patients' attitudes towards and experiences of generic drug substitution in Norway
    Inge Kjoenniksen
    Institute for Pharmacy Practice Research, Kalfarveien 31, N-5018, Bergen, Norway
    Pharm World Sci 28:284-9. 2006
  5. ncbi Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 47:319-25. 2009
  6. ncbi Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000
    Jennifer S Haas
    Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
    Ann Intern Med 142:891-7. 2005
  7. ncbi Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals
    Karolina Andersson
    Social Medicine, Department of Public Health and Community Medicine, Sahlgrenska Academy at Goteborg University, P O Box 453, SE 405 30 Goteborg, Sweden
    Health Policy 81:376-84. 2007
  8. ncbi Differences in persistence among different weekly oral bisphosphonate medications
    O Sheehy
    Pharmacoepidemiology and Pharmacoeconomics Research Unit, Centre Hospitalier de l Universite de Montreal, 3850 Saint Urbain, Pavillon Masson, Montreal, QC H2W 1T7, Canada
    Osteoporos Int 20:1369-76. 2009
  9. ncbi Authorized generic drugs, price competition, and consumers' welfare
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:790-9. 2007
  10. ncbi The unlicensed lives of antidepressants in India: generic drugs, unqualified practitioners, and floating prescriptions
    Stefan Ecks
    University of Edinburgh, Edinburgh, UK
    Transcult Psychiatry 46:86-106. 2009

Research Grants

  1. Periventricular White Matter Injury Prevention
    Scott A Rivkees; Fiscal Year: 2010
  2. Designing drugs that suppress chronic brain inflammation
    DAVID VIA; Fiscal Year: 2005
  3. An intervention to improve rational prescribing in cardiovascular disease
    William Shrank; Fiscal Year: 2007
  4. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
  5. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2010
  6. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden Huskamp; Fiscal Year: 2009
  7. Economics of Formulary Design and Mental Health Policy
    Haiden Huskamp; Fiscal Year: 2006
  8. Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
    Haiden A Huskamp; Fiscal Year: 2010
  9. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2011
  10. Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
    Haiden Huskamp; Fiscal Year: 2009

Detail Information

Publications239 found, 100 shown here

  1. ncbi Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia
    Nicole Gebran
    Pharmacy Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    Ann Saudi Med 26:192-9. 2006
    ..We assessed the quality of written prescribing information for selected generic drugs marketed in Saudi Arabia and manufactured in various countries of the Middle East.
  2. ncbi Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes
    Frederick Andermann
    Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
    Epilepsia 48:464-9. 2007
    ....
  3. ncbi A comparative analysis of generics markets in five European countries
    L Garattini
    Center for Health Economics CESAV, Mario Negri Institute for Pharmacolological Research, Ranica, Bergamo, Italy
    Health Policy 51:149-62. 2000
    ..Such an environment has stimulate the success of unbranded generics by delegating strong purchasing power to distributors...
  4. ncbi Patients' attitudes towards and experiences of generic drug substitution in Norway
    Inge Kjoenniksen
    Institute for Pharmacy Practice Research, Kalfarveien 31, N-5018, Bergen, Norway
    Pharm World Sci 28:284-9. 2006
    ..The lack of correlation between patient experiences and age, gender, and medical regimen complexity is interesting and should be investigated further...
  5. ncbi Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 47:319-25. 2009
    ..Insurers and policymakers strive to stimulate more cost-effective prescribing and, increasingly, are educating beneficiaries about generics...
  6. ncbi Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000
    Jennifer S Haas
    Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
    Ann Intern Med 142:891-7. 2005
    ..Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution...
  7. ncbi Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals
    Karolina Andersson
    Social Medicine, Department of Public Health and Community Medicine, Sahlgrenska Academy at Goteborg University, P O Box 453, SE 405 30 Goteborg, Sweden
    Health Policy 81:376-84. 2007
    ..This suggests that generic substitution has contributed to a reduction in the growth of pharmaceutical expenditure...
  8. ncbi Differences in persistence among different weekly oral bisphosphonate medications
    O Sheehy
    Pharmacoepidemiology and Pharmacoeconomics Research Unit, Centre Hospitalier de l Universite de Montreal, 3850 Saint Urbain, Pavillon Masson, Montreal, QC H2W 1T7, Canada
    Osteoporos Int 20:1369-76. 2009
    ..Persistence to weekly oral preparations remains suboptimal, particularly in patients who receive generic alendronate. Alternative solutions are needed to improve the real life effectiveness of osteoporosis therapies...
  9. ncbi Authorized generic drugs, price competition, and consumers' welfare
    Ernst R Berndt
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:790-9. 2007
    ..We posit that long-run prices and shares are likely essentially unaffected by authorized generics and that potential costs to consumers from any delayed generic entry are likely small...
  10. ncbi The unlicensed lives of antidepressants in India: generic drugs, unqualified practitioners, and floating prescriptions
    Stefan Ecks
    University of Edinburgh, Edinburgh, UK
    Transcult Psychiatry 46:86-106. 2009
    ....
  11. ncbi [Generic drugs instead of brand drugs prescriptions--long overdue]
    Siri Nelson
    Institutt for laboratoriemedisin, barne- og kvinnesykdommer, Det medisinske fakultet, Norges teknisk-naturvitenskapelige universitet, 7489 Trondheim
    Tidsskr Nor Laegeforen 126:441-3. 2006
    ..INTERPRETATION: Available data suggest that generic prescribing of drugs should be encouraged. Generic prescribing is likely to improve patient safety by assuring that the prescribed drug is in fact what is dispensed...
  12. ncbi Side effects of generic competition?
    Jörgen Hellström
    Department of Economics, Umea University, Sweden
    Eur J Health Econ 5:203-8. 2004
    ..Generic substitution laws and measures to increase generic competition may thus have unintended consequences since these results show a positive relationship between generic market shares and reported side effects...
  13. ncbi Brand and generic medications: are they interchangeable?
    Abdulrazaq S Al-Jazairi
    Department of Pharmacy Services, King Faisal Specialist Hospital and Research Center, Saudi Pharmaceutical Industries and Medical Appliances Corporation and the cCollege of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    Ann Saudi Med 28:33-41. 2008
    ..Our objective was to review and examine the basis of the controversy surrounding brand and generic interchangeability and to explore a practical approach in pursuing a switch...
  14. ncbi Generic substitution of antihypertensive drugs: does it affect adherence?
    Boris L G Van Wijk
    Department of Pharmacoepidemiology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Ann Pharmacother 40:15-20. 2006
    ..However, pharmacists and physicians often find that patients and brand-name manufacturers have doubt about the equivalence of the substituted drug. This may be reflected by decreased adherence to therapy...
  15. ncbi What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden
    Karolina Andersson
    Department of Social Medicine, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Pharmacoepidemiol Drug Saf 14:341-8. 2005
    ..The aim of the present study was to investigate obstacles to generic substitution and savings achieved during the first year after Sweden introduced generic substitution in October 2002...
  16. ncbi Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate
    Monjed Shakweh
    Laboratoire de Physicochimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Universite Paris Sud, Chatenay Malabry, France
    Eur J Pharm Sci 31:262-70. 2007
    ..The demonstrated differences in adhesiveness suggest that differences in oesophageal tolerance between Fosamax tablets and generics of sodium alendronate may exist...
  17. ncbi Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects
    Alan C Perkins
    Academic Medical Physics and Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom
    Clin Ther 30:834-44. 2008
    ....
  18. ncbi Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime
    Ekaterini Mastoraki
    Department of Surgical Intensive Care Unit, Onassis Cardiac Surgery Center, 356 Sygrou Ave, 17674 Athens, Greece
    J Infect 56:35-9. 2008
    ....
  19. ncbi Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy
    K Liow
    Via Christi Comprehensive Epilepsy Center, University of Kansas School of Medicine-Wichita, Wichita, KS 67214-3800, USA
    Neurology 68:1249-50. 2007
  20. ncbi Therapeutic equivalency of generic antiepileptic drugs: results of a survey
    Andrew N Wilner
    Suite 317, Americas Building, Newport, RI 02840, USA
    Epilepsy Behav 5:995-8. 2004
    ..Fifty-two (18.4%) neurologists agreed that the Food and Drug Administration standards for AED bioavailability are sufficiently narrow; 231 (81.6%) did not...
  21. ncbi Are all aciclovir cream formulations bioequivalent?
    L Trottet
    GlaxoSmithKline, Weybridge, Surrey, UK
    Int J Pharm 304:63-71. 2005
    ..Given the magnitude of the differences seen, there is concern over therapeutic inequivalence of generic ACV creams to the innovator cream...
  22. ncbi European healthcare policies for controlling drug expenditure
    Silvia M Ess
    Hirslanden Research, Zurich, Switzerland
    Pharmacoeconomics 21:89-103. 2003
    ..To control costs, the use of generic drugs is encouraged in most countries, but only few countries allow pharmacists to substitute generic drugs for ..
  23. ncbi What's the problem with generic antiepileptic drugs?: a call to action
    Michel J Berg
    Neurology 68:1245-6. 2007
  24. ncbi Generic substitution in the treatment of epilepsy: patient and physician perceptions
    Michel J Berg
    Department of Neurology, University of Rochester Medical Center and Strong Epilepsy Center, Rochester, NY, USA
    Epilepsy Behav 13:693-9. 2008
    ..Additional investigation on bioequivalence may help address ongoing concerns and inform policy-making decisions...
  25. ncbi Antiepileptic drugs: generic versus branded treatments
    Dominic C Heaney
    Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
    Lancet Neurol 6:465-8. 2007
    ..mean that substantial drug-budget savings may be possible by switching from innovator brands to cheaper generic drugs. Such savings have been achieved in many other treatment areas...
  26. ncbi Clinical consequences of generic substitution of lamotrigine for patients with epilepsy
    J LeLorier
    Centre de Recherche, Centre Hospitalier de l Universite de Montreal, Montreal, Canada
    Neurology 70:2179-86. 2008
    ....
  27. ncbi Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers
    Rachel A Bongiorno
    University of Maryland School of Pharmacy, Baltimore, Maryland, USA
    Semin Thromb Hemost 30:619-26. 2004
    ..These perceptions may change over time as additional data showing comparative therapeutic outcomes between generic and brand name formulations are published...
  28. ncbi Incentives and pharmaceutical reimbursement reforms in Spain
    Jaume Puig-Junoy
    Research Centre for Health and Economics CRES, Department of Economics and Business, Pompeu Fabra University, C Trias Fargas 25 27, 34 08005 Barcelona, Spain
    Health Policy 67:149-65. 2004
    ..In the final section of this paper, we present an overall assessment of the impact of these pharmaceutical reimbursement policies on the behaviour of the agents in the pharmaceutical market...
  29. ncbi Should newly diagnosed epilepsy be treated with generics?
    Peter Wolf
    Copenhagen University Hospital, Copenhagen and at the Danish Epilepsy Centre, Dianalund, Denmark
    Nat Clin Pract Neurol 4:176-7. 2008
  30. ncbi In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 61:76-9. 2008
    ..The average -16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h)...
  31. ncbi [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients]
    Ghazaleh Gouya
    Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Austria
    Wien Klin Wochenschr 120:89-95. 2008
    ..In collaboration with a company health insurance with 3143 members we analysed the economic benefit of reduced prescription fees for generic drugs in a 12-month period.
  32. ncbi Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting
    Jessica H Oyugi
    Epidemiology and Prevention Interventions Center and San Francisco General Hospital AIDS Program, University of California at San Francisco, San Francisco, CA 94143, USA
    J Acquir Immune Defic Syndr 36:1100-2. 2004
    ..The relative ease of administration of the 30-day visual analog scale suggests that this may be the preferred method to assess adherence in resource-poor settings...
  33. ncbi Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists
    Benoit Allenet
    Clinical Pharmacy Department, Grenoble School of Pharmacy, France Pavillon Moidieu, CHU de Grenoble, 38700 La Tronche, France
    Pharm World Sci 25:197-202. 2003
    In 1999, a new law was introduced, giving French pharmacists the right to switch from branded to generic drugs, unless the prescriber had specified that substitution was not permitted...
  34. ncbi Global health and university patents
    Amy Kapczynski
    Science 301:1629. 2003
  35. ncbi Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans
    Michael A Fischer
    Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA
    Health Serv Res 38:1051-63. 2003
    ..for generic versions of the same agent, to estimate the level of unrealized savings from use of substitutable generic drugs. We also examined whether variation in prices between states represented a potential source of unrealized ..
  36. ncbi The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine
    Mei Sheng Duh
    Analysis Group, Inc, Boston, Massachusetts 02199, USA
    Dis Manag 10:216-25. 2007
    ..Payers may weigh smaller-than-expected cost reductions against a possible decrease in effectiveness to assess the relevance of mandatory generic switching of lamotrigine...
  37. ncbi [The clinical and economic impact of generic drugs in the treatment of epilepsy]
    A Argumosa
    Department of Neuropediatrics, Hospital Universitario Marques de Valdecilla, University of Cantrabria, , E-39008 Santander, Cantabria, Spain
    Rev Neurol 41:45-9. 2005
    ....
  38. ncbi The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs
    Giuseppe Borgheini
    Neurological and Psychiatric Department, University of Padua, and Casa di Cura Parco dei Tigli, Padua, Italy
    Clin Ther 25:1578-92. 2003
    ..However, bioequivalence and therapeutic effectiveness are not necessarily the same...
  39. ncbi The ongoing regulation of generic drugs
    Richard G Frank
    Harvard Medical School, Boston, USA
    N Engl J Med 357:1993-6. 2007
  40. ncbi Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy
    Lisa S Haskins
    Harris Interactive Health Care Division, Rochester, NY, USA
    Epilepsy Behav 7:98-105. 2005
    ..Further evidence is required to understand how costs and effects of generic AED substitution affect patient welfare...
  41. ncbi Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia
    P McManus
    Drug Utilisation Sub Committee MDP 83, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, Australia
    Pharmacoepidemiol Drug Saf 10:295-300. 2001
    ....
  42. ncbi Progress in methodologies for evaluating bioequivalence of topical formulations
    V P Shah
    Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, USA
    Am J Clin Dermatol 2:275-80. 2001
    ..However, confidence in this methodology needs to be established, particularly regarding its relevance to clinical drug efficacy...
  43. ncbi Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE
    Gunter Kramer
    Epilepsia 48:609-11. 2007
  44. ncbi Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults
    Mina C Hosseinipour
    University of North Carolina Project, Lilongwe Malawi
    AIDS 21:59-64. 2007
    ..The Malawian antiretroviral program uses generic Triomune (stavudine, lamivudine, and nevirapine)...
  45. ncbi Economics and structure of the generic pharmaceutical industry
    D M Kirking
    Department of Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor 48109 1065, USA
    J Am Pharm Assoc (Wash) 41:578-84. 2001
    ..To review key economic trends of the generic medication market and analyze the changing structure of the generic medication industry...
  46. ncbi Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia
    Carlos A Rodriguez
    GRIPE Grupo Investigador de Problemas en Enfermedades Infecciosas, University of Antioquia Medical School, Medellin, Colombia
    J Infect 59:277-80. 2009
    ..It raises concern about therapeutic equivalence of generic vancomycin...
  47. ncbi Consumer perceptions of risk and required cost savings for generic prescription drugs
    J M Ganther
    Sonderegger Research Center, School of Pharmacy, University of Wisconsin, Madison, USA
    J Am Pharm Assoc (Wash) 40:378-83. 2000
    ....
  48. ncbi Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model
    Andres F Zuluaga
    Department of Pharmacology and Toxicology, University of Antioquia Medical School, Medellin, Colombia
    PLoS ONE 5:e10744. 2010
    ..Recent reports of deaths associated with generic heparin and metoprolol have raised concerns about the efficacy and safety of DRA-approved drugs...
  49. ncbi Examining the production costs of antiretroviral drugs
    Eloan Pinheiro
    Department of HIV/AIDS, World Health Organization, Geneva, Switzerland
    AIDS 20:1745-52. 2006
    ..The ability to achieve price reductions in line with production costs will have critical implications for sustainable treatment for HIV/AIDS in the developing world...
  50. ncbi The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma
    Vicki Fung
    Center for Health Policy Studies, Kaiser Permanente Division of Research, Oakland, California, USA
    BMC Health Serv Res 8:151. 2008
    ..We examined changes in ICS use following the introduction of generic-only coverage in a Medicare Advantage population from 2003-2004...
  51. ncbi Generic substitution: issues for problematic drugs
    J D Henderson
    Department of Physician Assistant Studies, College of Allied Health Professions, University of South Alabama College of Medicine, Mobile, USA
    South Med J 94:16-21. 2001
    ..Yet, misinformation and myths persist regarding the adequacy and proven reliability of the FDA's determination of bioequivalence for these products...
  52. ncbi Issues in the use of generic antiarrhythmic drugs
    J A Reiffel
    Cardiology Division, Department of Medicine, Columbia University, College of Physician and Surgeons and The Arrhythmia Service, Columbia-Presbyterian Medical Center Campus, The New York Presbyterian Hospital, New York, New York, USA
    Curr Opin Cardiol 16:23-9. 2001
    ..Additionally, guidelines for allowance or avoidance of antiarrhythmic drug formulation substitution are suggested...
  53. ncbi [How do practitioners evaluate the newly introduced system of substituting prescriptions?]
    S L Rubak
    Aarhus Universitet, Institut for Almen Medicin
    Ugeskr Laeger 162:6070-3. 2000
    ..The purpose of this study was to obtain the GPs' views on the system and evaluate the problems related to the system...
  54. ncbi Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies
    J Kersnik
    Department of Family Medicine, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
    J Clin Pharm Ther 31:577-83. 2006
    ..Substitution of branded products by generic equivalents can offer savings. General practitioners (GPs) are often concerned about the quality of generic products and possible legal liabilities associated with their use...
  55. ncbi Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs
    Emilio Perucca
    Clinical Pharmacology Unit and Institute of Neurology IRCCS C Mondino Foundation, University of Pavia, Pavia, Italy
    Epilepsia 47:16-20. 2006
    ....
  56. ncbi In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US
    Richard J Dansereau
    Procter and Gamble Pharmaceuticals, Mason, OH, USA
    Curr Med Res Opin 25:449-52. 2009
    ....
  57. ncbi Patient perception of generic antiepileptic drugs in the Midwestern United States
    Tania Beltran Papsdorf
    University of Kansas School of Medicine Wichita, Wichita, KS 67214 3199, USA
    Epilepsy Behav 14:150-3. 2009
    ..The goal of the study described here was to understand patients' experiences with generic AEDs in the Midwestern United States...
  58. ncbi A physician survey on generic drugs and substitution of critical dose medications
    B F Banahan
    Research Institute of Pharmaceutical Sciences, University of Mississippi, USA
    Arch Intern Med 157:2080-8. 1997
    ..the Food and Drug Administration standards for bioequivalency, especially with respect to narrow therapeutic index drugs, the awareness and attitudes of prescribing physicians to generic drugs and generic substitution are important.
  59. ncbi Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures
    M J Berg
    Strong Epilepsy Center, University of Rochester Medical Center, Rochester, NY 14642 8673, USA
    Neurology 71:525-30. 2008
    ..There are concerns that generic and brand antiepileptic drugs (AEDs) may not be therapeutically equivalent. This study investigated how generic AED substitution may have negative consequences...
  60. ncbi Prescribing indicators and their use by primary care groups to influence prescribing
    M Ashworth
    GKT Department of General Practice and Primary Care, King s College London, Lambeth Walk, London, UK
    J Clin Pharm Ther 27:197-204. 2002
    ....
  61. ncbi Drug product selection: legal issues
    T P Christensen
    College of Pharmacy, North Dakota State University, Fargo 58105, USA
    J Am Pharm Assoc (Wash) 41:868-74. 2001
    ..To review the potential legal liability of the pharmacist in the drug product selection process...
  62. ncbi Brand versus generic alendronate: gastrointestinal effects measured by resource utilization
    Hillel Halkin
    Chairman, Formulary Committee, Maccabi Healthcare Services, Tel Aviv, Israel Sackler School of Medicine, Tel Aviv University
    Ann Pharmacother 41:29-34. 2007
    ..Adverse reactions related to the upper gastrointestinal tract (UGIT) that are associated with generic alendronate formulations may differ from those associated with the brand drug...
  63. ncbi Determinants of prescribing costs amongst single-handed general practitioners
    P S Gill
    Department of Primary Care and General Practice, University of Birmingham, Birmingham, UK
    J Clin Pharm Ther 26:433-5. 2001
    ..To investigate the contribution of patient and doctor characteristics in explaining observed variations in prescribing costs between individual doctors...
  64. ncbi Strategies for acquiring affordable medications for seniors
    Kathy J Morris
    Council Bluffs Community Health Center, 300 West Broadway, Suite 6, Council Bluffs, IA, 51503, USA
    Nurs Clin North Am 40:51-62, vi. 2005
    ..Some community healthcenters offer access to prescriptions at decreased costs through fed-eral programs. This article explores the various options availableto senior citizens so that nurses may act as advocates for thesepatients...
  65. ncbi In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response
    Shayne Grice
    University of Otago, New Zealand
    N Z Bioeth J 4:22-4. 2003
  66. ncbi [The war on generic drugs]
    J Sternon
    Rev Med Brux 27:420-1. 2006
  67. ncbi Generic products of antiepileptic drugs (AEDs): is it an issue?
    Meir Bialer
    Department of Pharmaceutics, School of Pharmacy and David R Bloom Center for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
    Epilepsia 48:1825-32. 2007
    ....
  68. ncbi In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response
    David Woolner
    MSD, New Zealand
    N Z Bioeth J 4:22, 25-6. 2003
  69. ncbi Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand
    Patricia M Danzon
    University of Pennsylvania, USA
    Front Health Policy Res 7:1-54. 2004
    ..S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales...
  70. ncbi Nondialysis (home) medication utilization and cost in diabetic and nondiabetic hemodialysis patients
    Harold J Manley
    University of Missouri-Kansas City School of Pharmacy, USA
    Nephrol News Issues 19:27-8, 33-4, 36-8. 2005
    ..Health care providers should be aware of the medication cost burden in HD patients. Efforts to decrease this burden, whether through pharmaceutical care, generic prescribing, or sampling programs, should be considered...
  71. ncbi Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA
    Arch Gen Psychiatry 62:435-41. 2005
    ..Many employers and health plans have adopted 3-tier formularies in an attempt to control costs for these and other drugs...
  72. ncbi Comparison of annual cost between brand and generic ocular beta-adrenergic blockers
    Hiroaki Ikeda
    Department of Pharmaceutical Services, Hiroshima University Hospital, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 0001, Japan
    Yakugaku Zasshi 125:463-7. 2005
    ..The annual cost depended on not only the price of the products but also on the total number of drops in one bottle and the usage. Annual cost data may be helpful in selecting ophthalmic products for treating glaucoma in Japan...
  73. ncbi Follow-on biologics: competition in the biopharmaceutical marketplace
    Joshua W Devine
    Social and Administrative Pharmacy, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    J Am Pharm Assoc (2003) 46:193-201; quiz 202-4. 2006
    ..To describe the implications of a follow-on biologic approval process with focus on current stakeholders, implications of the status quo, and recommendations for future policy...
  74. ncbi Generic drugs: an overview
    Dave Helgeland
    Pharmacy Administration, South Dakota State University College of Pharmacy, USA
    S D Med 59:161-3. 2006
  75. ncbi [Generic drugs in the treatment of epilepsy]
    J Gonzalez de Dios
    Departamento de Pediatria, Hospital Universitario San Juan, Universidad Miguel Hernandez, San Juan, Alicante, Spain
    Rev Neurol 41:676-83. 2005
    We discuss some controversial aspects with prescription of generic drugs (GD) and the problems concerning bioequivalence, mainly in the case of drugs with non-linear pharmacokinetics and/or narrow therapeutic rank, like the antiepileptic ..
  76. ncbi The impact of generic substitution on price competition in Finland
    Ville Aalto-Setälä
    Faculty of Pharmacy, University of Helsinki, P O Box 56, 00014, Helsinki, Finland
    Eur J Health Econ 9:185-91. 2008
    ..The most important factors that influenced the price development were the number of competitors, whether the drug was originator or generic and the width of the price band...
  77. ncbi Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value
    Haiden A Huskamp
    Harvard Medical School, Boston, Massachusetts, USA
    Health Aff (Millwood) 25:635-46. 2006
    ....
  78. ncbi [Now no new drugs will be developed!]
    Pierre Lafolie
    Klinisk farmakologi, Karolinska Universitetssjukhuset Solna
    Lakartidningen 103:225. 2006
  79. ncbi Product-line extensions and pricing strategies of brand-name drugs facing patent expiration
    Song Hee Hong
    Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Manag Care Pharm 11:746-54. 2005
    ..price rigidity of patent-expired brand-name prescription drugs despite the increase in market entry of generic drugs facilitated by the 1984 Drug Price Competition and Patent Term Restoration Act...
  80. ncbi Generics market in Greece: the pharmaceutical industry's beliefs
    Mary Geitona
    Department of Economics, University of Thessaly, 43 Korai Str, Volos 38 221, Greece
    Health Policy 79:35-48. 2006
    ..Finally, the respondents expressed their preference for the introduction of pharmacoeconomic submissions for drugs' reimbursement by social insurance funds...
  81. ncbi PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists
    Andrew Davies
    N Z Med J 118:U1621. 2005
  82. ncbi Drug importation and safety of drugs obtained from Canada
    Marv Shepherd
    Center for Pharmacoeconomic Studies, College of Pharmacy, University of Texas, Austin, TX 78712, USA
    Ann Pharmacother 41:1288-91. 2007
    ..The US needs to become innovative and seek solutions that will provide effective, safe, and economical pharmaceuticals without placing a burden on other countries and without damaging the pharmaceutical research...
  83. ncbi Pharmaceutical promotion and GP prescription behaviour
    Frank Windmeijer
    Centre for Microdata Methods and Practice, Institute for Fiscal Studies, London, UK
    Health Econ 15:5-18. 2006
    ..We conclude that GP drug price sensitivity is small, but adversely affected by promotion. Ltd...
  84. ncbi Economic aspects of the new Spanish laws on pharmaceutical preparations
    Fernando Antonanzas
    Department of Economics and Business Administration, Universidad de La Rioja, C La Cigüena 60, 26004, Logrono, Spain
    Eur J Health Econ 8:297-300. 2007
    ..We review information on pricing, reference pricing, promotion of generic drugs, public reimbursement, patients' contributions, and penalties...
  85. ncbi Increasing generic drug use in Medicare Part D: the role of government
    Herb Kohl
    United States Senator from Wisconsin, Majority Leader, U.S. Senate Special Committee on Aging, 2nd and C St, NE, 330 Hart Senate Office Building, United States Senate, Washington, DC 20510, USA
    J Am Geriatr Soc 55:1106-9. 2007
  86. ncbi [Original or generic?]
    Iván György Magyar
    Neuropsychopharmacol Hung 7:167-8. 2005
  87. ncbi Managing prescription drug costs
    J M Sica
    Aon Consulting, Conshohocken, Pennsylvania, USA
    Empl Benefits J 26:35-40. 2001
    ..The author also discusses pharmacy benefit managers, as well as various utilization management strategies like benefit plan design and the use of formularies...
  88. ncbi Getting serious about generics
    Martin Sipkoff
    Manag Care 12:36-9. 2003
  89. ncbi Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Nina Pavenik
    Dartmouth College, USA
    Rand J Econ 33:469-87. 2002
    ..Price declines are most pronounced for brand-name products. Moreover, branded products that face more generic competitors reduce prices more...
  90. ncbi The high price of prescription drugs and its impact on the elderly
    Amanda McCloskey
    Families USA, 1334 G Street, NW, Washington, DC 20005, USA
    Care Manag J 3:143-53. 2002
  91. ncbi Lowering the cost of prescription drugs
    Bobby Jindal
    US Department of Health and Human Services, USA
    J La State Med Soc 155:51. 2003
  92. ncbi Impact of health plan design and management on retirees' prescription drug use and spending, 2001
    Cindy Parks Thomas
    Schneider Institute for Health Policy, Brandeis University, Waltham, Massachusetts, USA
    Health Aff (Millwood) . 2002
    ..Although we did not find lower rates of use in plans with aggressive cost sharing, this may be attributable in part to their higher drug use associated with mail-order incentives...
  93. ncbi AWP reimbursement scrutinized by several states
    John Carroll
    Manag Care 12:11-2. 2003
  94. ncbi Reference pricing for drugs: is it compatible with U.S. health care?
    Panos Kanavos
    Harvard Medical School, USA
    Health Aff (Millwood) 22:16-30. 2003
    ..This paper explores the difficult trade-offs that policymakers must make in designing such a system, drawing where relevant from experience abroad...
  95. ncbi Good science and the marketplace for drugs: a conversation with Jean-Pierre Garnier. Interview by John K. Iglehart
    Jean-Pierre Garnier
    GlaxoSmithKline
    Health Aff (Millwood) 22:119-27. 2003
  96. ncbi Financial consequences of drug benefit plans
    Brenda Motheral
    JAMA 289:423-4; author reply 424. 2003
  97. ncbi Financial consequences of drug benefit plans
    John Hsu
    JAMA 289:423; author reply 424. 2003
  98. ncbi [Generics: essentially similar, bioequivalent but not identical]
    D Even-Adin
    Hopital Erasme, U L B
    Rev Med Brux 22:513-20. 2001
    ..However, in term of economy, in the drug market, development of GF appears to constitute an unavoidable phenomenon...
  99. ncbi The economics of prescription drug prices, government intervention, and the importation of drugs from Canada
    Matthew S Openshaw
    Public Policy and Political Economy, University of Texas at Dallas, Dallas, TX, USA
    Nurs Econ 23:307-11, 279. 2005
    ..What effects would this have on consumer prices, drug companies' incentives, and the development of new medications?..
  100. ncbi The impact of drug samples on prescribing to the uninsured
    David P Miller
    Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157 1051, USA
    South Med J 101:888-93. 2008
    ..To determine whether drug samples are associated with physicians prescribing fewer generic, less costly medications...
  101. ncbi Employer drug benefit plans and spending on prescription drugs
    Geoffrey F Joyce
    RAND Health, 1700 Main St, Santa Monica, CA 90407 2138, USA
    JAMA 288:1733-9. 2002
    ..It is unknown how these initiatives affect drug costs...

Research Grants110 found, 100 shown here

  1. Periventricular White Matter Injury Prevention
    Scott A Rivkees; Fiscal Year: 2010
    ..avoid the high costs and the lengthy time frame associated with new drug development in applying FDA-approved, generic drugs for novel clinical applications...
  2. Designing drugs that suppress chronic brain inflammation
    DAVID VIA; Fiscal Year: 2005
    ..Since the ultimate goal of therapeutic strategies for AD is to protect neurons, we screened a variety of generic drugs for neuroprotective effect using cell culture and animals models of AD immune pathology...
  3. An intervention to improve rational prescribing in cardiovascular disease
    William Shrank; Fiscal Year: 2007
    ..End of Abstract) ..
  4. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  5. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2010
    ..We will estimate a combination of two-part random-effects models for longitudinal data, latent class random-effects models, logistic regression models, Poisson regression models, and hazard models to address these aims. ..
  6. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden Huskamp; Fiscal Year: 2009
    ..We will estimate a combination of two-part random-effects models for longitudinal data, latent class random-effects models, logistic regression models, Poisson regression models, and hazard models to address these aims. ..
  7. Economics of Formulary Design and Mental Health Policy
    Haiden Huskamp; Fiscal Year: 2006
    ..Huskamp the training, mentoring, time and resources to develop the skills that will put her in a position to lead independent research on the economics of pharmaceutical treatment for mental illnesses. ..
  8. Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
    Haiden A Huskamp; Fiscal Year: 2010
    ....
  9. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2011
    ..We will estimate a combination of two-part random-effects models for longitudinal data, latent class random-effects models, logistic regression models, Poisson regression models, and hazard models to address these aims. ..
  10. Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
    Haiden Huskamp; Fiscal Year: 2009
    ....
  11. Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
    YA CHEN SHIH; Fiscal Year: 2009
    ..This information will help project the future costs of cancer. Findings from this study will also alert policymakers to the subgroups of patients who may not benefit from innovative agents such as mAbs due to access barriers. ..
  12. Clinical Implications of Variation Among Medicare Formularies
    Chien Wen Tseng; Fiscal Year: 2007
    ....
  13. Seniors' health literacy, beliefs and asthma self-management
    Alex Federman; Fiscal Year: 2009
    ..The study findings will expand our understanding of health literacy and provide new insights into best methods for educating older asthmatics about managing their disease. ..
  14. BIOMEDICAL RESEARCH TRAINING IN DRUG ABUSE
    THEODORE CICERO; Fiscal Year: 2006
    ..abstract_text> ..
  15. Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer
    YA CHEN SHIH; Fiscal Year: 2007
    ..To estimate the budgetary impact of the emerging pharmacogenomic prognostic and/or predictive tests ..
  16. Molecular Genetics of Inattention in Australia
    THEODORE CICERO; Fiscal Year: 2009
    ..This will be at a marked cost savings due to the employment of existing well-characterized samples and the long history of collaborative studies between investigators from Australia and the United States. ..
  17. Advanced Training in Health Service Research
    Patricia Danzon; Fiscal Year: 2007
    ....
  18. BIOMEDICAL RESEARCH TRAINING IN DRUG ABUSE
    THEODORE CICERO; Fiscal Year: 2007
    ....
  19. OPIATE ENDOCRINE INTERACTIONS--DEVELOPMENTAL ASPECTS
    THEODORE CICERO; Fiscal Year: 2003
    ..The proposed animal studies could establish whether gender differences exist and if these differences are based on inherent, first-order biological differences between the sexes. ..
  20. OPIATE-ENDOCRINE INTERACTIONS; DEVELOPMENTAL ASPECTS
    THEODORE CICERO; Fiscal Year: 1992
  21. Reducing Cost-Related Medication Nonadherence in Persons with Diabetes
    Chien Wen Tseng; Fiscal Year: 2010
    ..If shown to be successful, the Prescribing Guide is practical and low-cost, and could easily be translated to other states, giving it tremendous potential to improve health nationwide. ..
  22. OPIATE-ENDOCRINE INTERACTIONS--DEVELOPMENTAL ASPECTS
    THEODORE CICERO; Fiscal Year: 1993
    ....
  23. Seniors' health literacy, beliefs and asthma self-management
    Alex D Federman; Fiscal Year: 2010
    ..The study findings will expand our understanding of health literacy and provide new insights into best methods for educating older asthmatics about managing their disease. ..
  24. Electronic Research Submission at Washington Univ
    THEODORE CICERO; Fiscal Year: 2002
    ..In addition, this infrastructure will make it possible for all compliance committees to share data to ensure the highest level of human subject protection. ..
  25. Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
    Ya Chen Tina Shih; Fiscal Year: 2010
    ..This information will help project the future costs of cancer. Findings from this study will also alert policymakers to the subgroups of patients who may not benefit from innovative agents such as mAbs due to access barriers. ..
  26. Specialty Mental Health Care--Expanding Access in an HMO
    Dominic Hodgkin; Fiscal Year: 2003
    ..The results will inform health plan decision-makers and others as they make utilization management choices that may have a major impact on patients and enrollee populations overall. ..
  27. Provision of Alcohol Services in Private Health Plans
    Constance Horgan; Fiscal Year: 2009
    ..s. ..
  28. Pharmacological Optimization of Poly-Drug Therapy in Traumatic Brain Injury
    Michael R Hoane; Fiscal Year: 2010
    ..This study will help to identify combinations of drugs that could be used to prevent the long-term effects. ..
  29. Provision of Alcohol Services in Private Health Plans
    Constance M Horgan; Fiscal Year: 2010
    ..This competitive renewal for Round 3 of our survey will provide a current picture of the complex and changing organization of behavioral health services in private health plans, which cover the majority of people under 65 in the U.S. ..
  30. Substrate requirements of the bile acid transporter
    JAMES POLLI; Fiscal Year: 2009
    ..This systematic and progressive approach will serve as a prototypical method to elucidate the substrate requirements of other solute carrier (SLC) proteins. ..
  31. Provision of Drug Abuse Treatment Services Under Parity
    Constance M Horgan; Fiscal Year: 2010
    ..s. ..
  32. High Purity Amphotericin B: A Safer Antimycotic in AIDS
    John Cleary; Fiscal Year: 2005
    ..abstract_text> ..
  33. Alcohol Treatment Under Managed Care Plans: Role of HMOs
    Constance Horgan; Fiscal Year: 2004
    ..This study will provide systematic information on the nature and extent of HMO changes, and their impact on alcohol service delivery, during this time period. ..
  34. DRUG ABUSE TREATMENT UNDER MANAGED CARE--ROLE OF PPOS
    Constance Horgan; Fiscal Year: 2002
    ..This study will provide systematic information on the nature and extent of these changes. ..
  35. Substrate requirements of the bile acid transporter
    JAMES POLLI; Fiscal Year: 2007
    ..This systematic and progressive approach will serve as a prototypical method to elucidate the substrate requirements of other solute carrier (SLC) proteins. ..
  36. Doctoral Training/Health Services Research on Alcohol
    Constance Horgan; Fiscal Year: 2007
    ..This unique approach to doctoral training has already established the Heller NIAAA Doctoral Training Program a success, as evidenced by the progress and commitment of the current and former trainees. ..
  37. Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions
    Awewura Kwara; Fiscal Year: 2007
    ....
  38. Access to Care: Children with Special Health Care Needs
    Alex Chen; Fiscal Year: 2007
    ..Phase II is the development of an access-to-care survey instrument and limited-scope primary data collection to further examines factors impacting access to care for CSHCN. ..
  39. Effective Care Management of Depressed Diabetes Patients
    John Piette; Fiscal Year: 2007
    ..The evaluation has been structured based on the RE-AIM framework for effectiveness trials. ..
  40. Epileptogenicity in the Developing Brain
    Raman Sankar; Fiscal Year: 2007
    ..Our findings will provide the basis for future neuroprotective interventions targeting the developing brain at different stages of status epilepticus in order to interrupt the course of the epileptogenic process. ..
  41. Pharmacogenomics/natural products + antifungal activity
    John Cleary; Fiscal Year: 2004
    ..Probing this array with eukaryotic mRNA from cells exposed to novel antifungals would predict common mechanism of action and likelihood of toxicity, activity and resistance. ..
  42. Impact of 3 Tier Drug Copays on Use and Spending
    Dominic Hodgkin; Fiscal Year: 2003
    ..abstract_text> ..